Recent Finacing
Recent Raise
Talee Bio develops inhaled, mutation-agnostic gene therapies for cystic fibrosis—TL-101 (aerosolized recombinant AAV) and TL-102 (aerosolized lentiviral)—in preclinical stages targeting pulmonary disease.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Spirovant.
